Seegene to secure a bridgehead for leading MDx market in Latin America 

Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies 
headquartered in South Korea, announced that it will export 10 million tests of 
its COVID-19 testing kits to Pan American Health Organization (PAHO) / World 
Health Organization (WHO) through Brazilian subsidiary, Seegene do Brasil 
Diagnosticos Ltda.

Seegene has supplied 5 million tests of Allplex(TM) 2019-nCOV assay to Brazil 
and will supply remaining tests in the following weeks. Also, Seegene will 
discuss a further increase of up to 100% of the testing volume. 

The company said, "This unprecedentedly large export volume emphasizes an 
explosive increase in demand for Seegene's COVID-19 product worldwide and 
demonstrates that our high volume testing system is gaining world recognition." 

Seegene's Allplex(TM) 2019-nCOV Assay is eyeing a good response from the market 
as the capability of the assay that identifies 3 different target genes (E 
gene, RdRP gene and N gene) in a single-tube enables accurate and efficient 
diagnosis, and Seegene's automated system is extremely useful during the 
coronavirus pandemic where large volume of tests are required. 

Seegene has already exported 20 million tests of the COVID-19 assays to over 60 
countries and is ramping up the production rapidly to meet an increased demand 
across the globe. 

The export volume to the Brazilian market is expected to rise as Seegene is 
negotiating supply agreement with the state government and private laboratories 
in Brazil. In addition, the company is planning with PAHO for further contracts 
with other countries in Latin America. 

As Seegene's assay is already well-recognized in major European countries such 
as France, Germany, Italy and Spain, the company's solution for COVID-19 
diagnosis surely secures a bridgehead for expanding the market presence to 
Latin America. This contract indeed marks a significant beginning for Seegene 
to further occupy the molecular diagnostics market in all of the countries in 
Latin America.  

About Seegene

Seegene (KQ : 096530) is a global pioneer in symptom-based in vitro molecular 
diagnostics focusing on advancing science to develop multiplex molecular 
technologies and to manufacture multiplex in vitro diagnostic devices and 
reagents. Seegene's core enabling power is the passion for wide spreading of 
multiplex molecular diagnostics to improve the quality of life and health of 
people. Using its innovative proprietary technologies, Seegene has been making 
considerable contributions to giving the most economic and clinic-friendly 
molecular diagnostic solutions for infectious diseases, genetics, 
pharmacogenetics, and oncology. For more information, please visit 
www.seegene.com.

Joon Kim
kjh8363@seegene.com

Jisoo Lee
jislee@seegene.com



SOURCE: Seegene